Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status.
Saved in:
| Title: | Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and TP53 mutation status. |
|---|---|
| Authors: | Freeman CL; H. Lee Moffitt Cancer Centre and Research Institute, Tampa, FL.; Morsani College of Medicine, University of South Florida, Tampa, FL., Srinivasan S; Johnson & Johnson, Spring House, PA., Hodkinson B; Johnson & Johnson, Spring House, PA., Deshpande S; Johnson & Johnson, Raritan, NJ., Henninger T; Johnson & Johnson, Raritan, NJ., Boyle M; BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada., Wang ML; Department of Lymphoma & Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Dreyling M; Department of Medicine III, Ludwig Maximilian University Hospital, Munich, Germany., Scott DW; BC Cancer Centre for Lymphoid Cancer, Vancouver, BC, Canada.; Department of Medicine, The University of British Columbia, Vancouver, BC, Canada. |
| Source: | Blood [Blood] 2025 Jun 19; Vol. 145 (25), pp. 3052-3056. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
